Skip to main content

Table 3 Overview of sensitivity analyses

From: Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial

Withdrawal reasons Assignment of patients in:
Primary analysis Sensitivity analysis
  A B C Da
The patient experiences a CIDP relapse during the SC treatment period (lack of efficacy) Relapser Relapser Relapser Relapser Relapser
The investigator advises that the patient’s safety or wellbeing could be compromised by further participation in the study (physician decision) Relapser Non-relapsers Relapser Not used for analysis Censored
The patient receives prohibited medication (protocol violation) Censored
Other withdrawal reason (other, adverse event, death, lost to follow-up, protocol violation, study termination by sponsor, and withdrawal by patient) Non-relapsers Censored
Patient continues to study end Non-relapsers Non-relapsers Non-relapsers Non-relapsers Non-relapsers
  1. CIPD chronic inflammatory demyelinating polyneuropathy, SC subcutaneous
  2. aExploratory sensitivity analysis